← Back to Search

Phosphodiesterase 4 (PDE4) inhibitor

Otezla for Psoriasis

Phase 4
Waitlist Available
Research Sponsored by Psoriasis Treatment Center of Central New Jersey
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks
Awards & highlights

Study Summary

Patients with moderate to severe plaque psoriasis will be treated with Otezla BID. At week 8, non responders will be discontinued, partial responders will be given add-on Enstilar QD for 4 weeks and PASI 75 responders will remain on Otezla monotherapy through week 16.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Psoriasis Area Severity Index 75 at week 12

Side effects data

From 2018 Phase 4 trial • 28 Patients • NCT03441789
14%
rhinorrhea
7%
abdominal cramping
7%
thrombocytopenia
7%
chronic obstructive pulmonary disease exacerbation
7%
upper respiratory infection
7%
sinus tachycardia
7%
shortness of air
7%
diarrhea
7%
overactive bladder
7%
right flank pain
7%
nausea
7%
dyspnea at rest
7%
squamous cell carcinoma
7%
increased joint pain generalized
7%
chest congestion
7%
fall at home
100%
80%
60%
40%
20%
0%
Study treatment Arm
Otezla Plus Enstilar Foam
Otezla Plus Vehicle Foam

Trial Design

1Treatment groups
Experimental Treatment
Group I: OtezlaExperimental Treatment1 Intervention
Otezla BID
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Apremilast
FDA approved

Find a Location

Who is running the clinical trial?

Psoriasis Treatment Center of Central New JerseyLead Sponsor
14 Previous Clinical Trials
392 Total Patients Enrolled
13 Trials studying Psoriasis
352 Patients Enrolled for Psoriasis
Celgene CorporationIndustry Sponsor
444 Previous Clinical Trials
58,186 Total Patients Enrolled
4 Trials studying Psoriasis
3,741 Patients Enrolled for Psoriasis

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Evaluation of Add on Enstilar in Patients Using Otezla for Psoriasis
2018. "Evaluation of Add on Enstilar in Patients Using Otezla for Psoriasis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03587194.
All > Psoriasis > Otezla
~7 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top